{
    "nct_id": "NCT03057600",
    "official_title": "A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry",
    "inclusion_criteria": "* Meets criteria for 1 of the 4 defined study cohorts\n* TNBC, defined as estrogen receptor (ER) and progesterone receptor (PR) negative (< 1% by immunohistochemistry) and human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization [FISH] negative)\n* Metastatic disease or locally-advanced disease not amenable to curative intent treatment\n* Adequate hepatic, renal, cardiac, and hematologic function\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version.4.0\n\nKey\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known brain metastases or central nervous system (CNS) cancer unless adequately treated with radiotherapy and/or surgery and stable for ≥ 2 mo\n* Unable to receive oral medications\n* Known hypersensitivity to Cremophor®-based agents\n* Major surgery within 28 days of Cycle 1 Day 1",
    "miscellaneous_criteria": "Key"
}